NCT04452370

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Chinese Academy of Medical Sciences · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The hypothesis of this study is to discover if the oral Etoposide plus Anlotinib can shrink or slow the growth of pretreated advanced TNBC. It is a single-arm, multicenter phase II clinical study of oral etoposide combined with antinib in the treatment of recurrent or metastatic triple-negative breast cancer

Detailed description

It is a single-arm, multicenter phase II clinical study of oral etoposide combined with antinib in the treatment of recurrent or metastatic triple-negative breast cancer. The hypothesis of this study is to discover if the oral Etoposide plus Anlotinib can shrink or slow the growth of pretreated advanced TNBC.

Conditions

• Triple Negative Breast Cancer

Interventions

Type	Name	Description
DRUG	oral etoposide + anlotinib	anlotinib 12mg qd, d1-14，21days/cycle oral etoposide 75mg qd，d1-10，21days/cycle

Timeline

• Start date: 2020-09-23
• Primary completion: 2022-07-11
• Completion: 2023-07-11
• First posted: 2020-06-30
• Last updated: 2021-07-21

Locations

1 site across 1 country: China